Ganciclovir
NDC 51754-2500
Product Information
Ganciclovir is a NDA-approved product labeled by Exela Pharma Sciences, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 51754-2500 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 51754-2500?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GANCICLOVIR (UNII: P9G3CKZ4P5)
- GANCICLOVIR (UNII: P9G3CKZ4P5) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1872065 - ganciclovir 500 MG in 250 mL Injection
- RxCUI: 1872065 - 250 ML ganciclovir 2 MG/ML Injection
- RxCUI: 1872065 - ganciclovir 500 MG per 250 ML Injection
* Please review the full disclaimer at the bottom of this page.
Patient Education
Ganciclovir Injection
Ganciclovir injection is used to treat cytomegalovirus (CMV) retinitis (eye infection that can cause blindness) in people whose immune system is not working normally, including those people who have acquired immunodeficiency syndrome (AIDS). It is also used to prevent CMV disease in transplant recipients at risk for CMV infection. Ganciclovir injection is in a class of medications called antivirals. It works by stopping the spread of CMV in the body.
[Learn More]
* Please review the full disclaimer at the bottom of this page.